Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BHP Billiton Limited (BHP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

BHP Billiton LimitedTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

BHP Billiton Limited vs Inovio Pharmaceuticals Inc — how do they compare? BHP Billiton Limited trades at $90.62 (market cap $229.15B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: BHP Billiton Limited is far larger — about 2917.3× Inovio Pharmaceuticals Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BHPINO
Market Cap
$229.15B$78.55M
Sector
Basic MaterialsHealth
52-Week High
$93.15$2.87
52-Week Low
$52.14$0.66
Enterprise Value
$243.35B$49.56M
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BHP Billiton Limited

BHP trades at $90.38, down 0.25% on the day, with a bullish technical signal driven by moving averages. The company reported Q4 2025 EPS of $2.24, missing expectations of $2.41, but maintains strong profitability with an 18.97% net income margin. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production, while institutional buying activity signals confidence.

Outlook is mixed: solid fundamentals and copper demand from AI data centers offer growth potential, but strikes and valuation concerns pose risks. Analysts are cautious with 64.52% hold ratings, reflecting balanced near-term uncertainty amid long-term resource strengths.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BHP Billiton Limited

BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.

Read more on BHP

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO